Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094929 | 0.89 | ALDH1A1 (0.56) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4014665 | 0.88 | CYP1A2 (0.63) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2436193 | 0.88 | CYP1A2 (0.63) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14333582 | 0.85 | CYP1A2 (0.49) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3601373 | 0.85 | POLB (0.58) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28448736 | 0.84 | ALDH1A1 (0.52) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29500851 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2NPC1RAB9AAKR1C3 | |
| SCHEMBL29848981 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9AMAOA | |
| SCHEMBL21061651 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2NPC1RAB9AAKR1C3 | |
| SCHEMBL28444987 | 0.83 | POLB (0.52) | HSD17B10ALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024152995-A1 | MACROCYCLIC CYCLIN INHIBITORS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海量医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| CN-112047933-B | Quinazolinone USP7 inhibitor and preparation method and application thereof | 郑州大学 | 2022-06-14 | — | — | CN | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| CN-112047933-A | Quinazolinone USP7 inhibitor and preparation method and application thereof | 郑州大学 | 2020-12-08 | — | — | CN | disclosed |
| EP-3724192-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2020-10-21 | — | — | EP | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| WO-2019116324-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2019-06-20 | — | — | WO | disclosed |
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20070067922-A1 | 4-Aminophenol derivatives and colorants comprising these compounds | PROCTER & GAMBLE COMPANY, THE | 2007-03-29 | — | — | US | disclosed |
| US-5686626-A | COGNITION ACTIVATORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5621116-A | CHEMICAL INTERMEDIATES; MEMORY ENHANCERS FOR TREATMENT OF ALZHEIMER*S, ANALGESICS, ANTICONVULSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5464846-A | Learning enhancement, Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0415102-B1 | 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-ones, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5179119-A | Cognition activators; alzheimer*s disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-01-12 | — | — | US | disclosed |
| US-5053511-A | Analgesics; anticonvulsants; treatment for alzheimers disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0415102-A1 | 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-ones, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | HSD17B10 2651/4885ALDH1A1 425/4885SMN1; SMN2 3515/4885 |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | HSD17B10 1459/4885ALDH1A1 1270/4885SMN1; SMN2 4312/4885 |
| US-20070067922-A1 | 4-Aminophenol derivatives and colorants comprising these compounds | KRT18, S100A4, CKAP4 | HSD17B10 1395/4885ALDH1A1 309/4885SMN1; SMN2 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.